Literature DB >> 32102946

Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial.

Kathleen Torkko1, Cathee Till2, Catherine M Tangen2,3, Phyllis J Goodman2, Xiaoling Song3, Jeannette M Schenk3, M Scott Lucia1, Ulrike Peters3, Adrie van Bokhoven1, Ian M Thompson4, Marian L Neuhouser5.   

Abstract

Vitamin D may influence prostate cancer risk, but evidence is inconsistent. We conducted a nested case-control study in the Prostate Cancer Prevention Trial (PCPT). Cases (n = 1,128) and controls (n = 1,205) were frequency matched on age, first-degree relative with prostate cancer, and PCPT treatment arm (finasteride/placebo); African-Americans were oversampled and case/control status was biopsy confirmed. We selected 21 SNPs in vitamin D-related genes (VDR, GC, C10orf88, CYP2R1, CYP24A1, CYP27B1, DHCR7, and NADSYN1) to test genotype and genotype-treatment interactions in relation to prostate cancer. We also tested mean serum 25(OH)D differences by minor allele distributions and tested for serum 25(OH)D-genotype interactions in relation to prostate cancer risk. Log-additive genetic models (Bonferroni-corrected within genes) adjusted for age, body mass index, PSA, and family history of prostate cancer revealed a significant interaction between treatment arm and GC/rs222016 (finasteride OR = 1.37, placebo OR = 0.85; P interaction < 0.05), GC/rs222014 (finasteride OR = 1.36, placebo OR = 0.85; P interaction < 0.05), and CYP27B1/rs703842 (finasteride OR = 0.76, placebo OR = 1.10; P interaction < 0.05) among Caucasians, and C10orf88/rs6599638 (finasteride OR = 4.68, placebo OR = 1.39; P interaction < 0.05) among African-Americans. VDR/rs1544410 and CYP27B1/rs703842 had significant treatment interactions for high-grade disease among Caucasians (finasteride OR = 0.81, placebo OR = 1.40; P interaction < 0.05 and finasteride OR = 0.70, placebo OR = 1.28; P interaction < 0.05, respectively). Vitamin D-related SNPs influenced serum 25(OH)D, but gene-serum 25(OH)D effect modification for prostate cancer was marginally observed only for CYP24A1/rs2248359. In conclusion, evidence that vitamin D-related genes or gene-serum 25(OH)D associations influence prostate cancer risk is modest. We found some evidence for gene-finasteride interaction effects for prostate cancer in Caucasians and African-Americans. Results suggest only minimal associations of vitamin D with total or high-grade prostate cancer. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32102946      PMCID: PMC7272271          DOI: 10.1158/1940-6207.CAPR-19-0413

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  36 in total

1.  Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.

Authors:  Sara Gandini; Mathieu Boniol; Jari Haukka; Graham Byrnes; Brian Cox; Mary Jane Sneyd; Patrick Mullie; Philippe Autier
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women.

Authors:  Marian L Neuhouser; JoAnn E Manson; Amy Millen; Mary Pettinger; Karen Margolis; Elizabeth T Jacobs; James M Shikany; Mara Vitolins; Lucile Adams-Campbell; Simin Liu; Erin LeBlanc; Karen C Johnson; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2012-02-22       Impact factor: 4.897

3.  The vitamin D status of the US population from 1988 to 2010 using standardized serum concentrations of 25-hydroxyvitamin D shows recent modest increases.

Authors:  Rosemary L Schleicher; Maya R Sternberg; David A Lacher; Christopher T Sempos; Anne C Looker; Ramon A Durazo-Arvizu; Elizabeth A Yetley; Madhulika Chaudhary-Webb; Khin L Maw; Christine M Pfeiffer; Clifford L Johnson
Journal:  Am J Clin Nutr       Date:  2016-07-06       Impact factor: 7.045

4.  A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.

Authors:  Ruth C Travis; Aurora Perez-Cornago; Paul N Appleby; Demetrius Albanes; Corinne E Joshu; Pamela L Lutsey; Alison M Mondul; Elizabeth A Platz; Stephanie J Weinstein; Tracy M Layne; Kathy J Helzlsouer; Kala Visvanathan; Domenico Palli; Petra H Peeters; Bas Bueno-de-Mesquita; Antonia Trichopoulou; Marc J Gunter; Konstantinos K Tsilidis; Maria-Jose Sánchez; Anja Olsen; Hermann Brenner; Ben Schöttker; Laura Perna; Bernd Holleczek; Paul Knekt; Harri Rissanen; Bu B Yeap; Leon Flicker; Osvaldo P Almeida; Yuen Yee Elizabeth Wong; June M Chan; Edward L Giovannucci; Meir J Stampfer; Giske Ursin; Randi E Gislefoss; Tone Bjørge; Haakon E Meyer; Rune Blomhoff; Shoichiro Tsugane; Norie Sawada; Dallas R English; Darryl W Eyles; Alicia K Heath; Elizabeth J Williamson; Jonas Manjer; Johan Malm; Martin Almquist; Loic Le Marchand; Christopher A Haiman; Lynne R Wilkens; Jeannette M Schenk; Cathy M Tangen; Amanda Black; Michael B Cook; Wen-Yi Huang; Regina G Ziegler; Richard M Martin; Freddie C Hamdy; Jenny L Donovan; David E Neal; Mathilde Touvier; Serge Hercberg; Pilar Galan; Mélanie Deschasaux; Timothy J Key; Naomi E Allen
Journal:  Cancer Res       Date:  2018-11-13       Impact factor: 12.701

5.  Interactions of PVT1 and CASC11 on Prostate Cancer Risk in African Americans.

Authors:  Hui-Yi Lin; Catherine Y Callan; Zhide Fang; Heng-Yuan Tung; Jong Y Park
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-03-26       Impact factor: 4.254

6.  Interactions Between Genome-Wide Significant Genetic Variants and Circulating Concentrations of 25-Hydroxyvitamin D in Relation to Prostate Cancer Risk in the National Cancer Institute BPC3.

Authors:  Vasiliki I Dimitrakopoulou; Ruth C Travis; Irene M Shui; Alison Mondul; Demetrius Albanes; Jarmo Virtamo; Antonio Agudo; Heiner Boeing; H Bas Bueno-de-Mesquita; Marc J Gunter; Mattias Johansson; Kay-Tee Khaw; Kim Overvad; Domenico Palli; Antonia Trichopoulou; Edward Giovannucci; David J Hunter; Sara Lindström; Walter Willett; J Michael Gaziano; Meir Stampfer; Christine Berg; Sonja I Berndt; Amanda Black; Robert N Hoover; Peter Kraft; Timothy J Key; Konstantinos K Tsilidis
Journal:  Am J Epidemiol       Date:  2017-03-15       Impact factor: 4.897

7.  Genome-wide association study of circulating vitamin D levels.

Authors:  Jiyoung Ahn; Kai Yu; Rachael Stolzenberg-Solomon; K Claire Simon; Marjorie L McCullough; Lisa Gallicchio; Eric J Jacobs; Alberto Ascherio; Kathy Helzlsouer; Kevin B Jacobs; Qizhai Li; Stephanie J Weinstein; Mark Purdue; Jarmo Virtamo; Ronald Horst; William Wheeler; Stephen Chanock; David J Hunter; Richard B Hayes; Peter Kraft; Demetrius Albanes
Journal:  Hum Mol Genet       Date:  2010-04-23       Impact factor: 6.150

Review 8.  Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review.

Authors:  Lina Chen; George Davey Smith; David M Evans; Angela Cox; Debbie A Lawlor; Jenny Donovan; Wei Yuan; Ian N M Day; Richard M Martin; Athene Lane; Santi Rodriguez; Michael Davis; Luisa Zuccolo; Simon M Collin; Freddie Hamdy; David Neal; Sarah J Lewis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

9.  Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk.

Authors:  Jiyoung Ahn; Demetrius Albanes; Sonja I Berndt; Ulrike Peters; Nilanjan Chatterjee; Neal D Freedman; Christian C Abnet; Wen-Yi Huang; Adam S Kibel; E David Crawford; Stephanie J Weinstein; Stephen J Chanock; Arthur Schatzkin; Richard B Hayes
Journal:  Carcinogenesis       Date:  2009-03-02       Impact factor: 4.944

10.  Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels.

Authors:  Xia Jiang; Paul F O'Reilly; Hugues Aschard; Yi-Hsiang Hsu; J Brent Richards; Josée Dupuis; Erik Ingelsson; David Karasik; Stefan Pilz; Diane Berry; Bryan Kestenbaum; Jusheng Zheng; Jianan Luan; Eleni Sofianopoulou; Elizabeth A Streeten; Demetrius Albanes; Pamela L Lutsey; Lu Yao; Weihong Tang; Michael J Econs; Henri Wallaschofski; Henry Völzke; Ang Zhou; Chris Power; Mark I McCarthy; Erin D Michos; Eric Boerwinkle; Stephanie J Weinstein; Neal D Freedman; Wen-Yi Huang; Natasja M Van Schoor; Nathalie van der Velde; Lisette C P G M de Groot; Anke Enneman; L Adrienne Cupples; Sarah L Booth; Ramachandran S Vasan; Ching-Ti Liu; Yanhua Zhou; Samuli Ripatti; Claes Ohlsson; Liesbeth Vandenput; Mattias Lorentzon; Johan G Eriksson; M Kyla Shea; Denise K Houston; Stephen B Kritchevsky; Yongmei Liu; Kurt K Lohman; Luigi Ferrucci; Munro Peacock; Christian Gieger; Marian Beekman; Eline Slagboom; Joris Deelen; Diana van Heemst; Marcus E Kleber; Winfried März; Ian H de Boer; Alexis C Wood; Jerome I Rotter; Stephen S Rich; Cassianne Robinson-Cohen; Martin den Heijer; Marjo-Riitta Jarvelin; Alana Cavadino; Peter K Joshi; James F Wilson; Caroline Hayward; Lars Lind; Karl Michaëlsson; Stella Trompet; M Carola Zillikens; Andre G Uitterlinden; Fernando Rivadeneira; Linda Broer; Lina Zgaga; Harry Campbell; Evropi Theodoratou; Susan M Farrington; Maria Timofeeva; Malcolm G Dunlop; Ana M Valdes; Emmi Tikkanen; Terho Lehtimäki; Leo-Pekka Lyytikäinen; Mika Kähönen; Olli T Raitakari; Vera Mikkilä; M Arfan Ikram; Naveed Sattar; J Wouter Jukema; Nicholas J Wareham; Claudia Langenberg; Nita G Forouhi; Thomas E Gundersen; Kay-Tee Khaw; Adam S Butterworth; John Danesh; Timothy Spector; Thomas J Wang; Elina Hyppönen; Peter Kraft; Douglas P Kiel
Journal:  Nat Commun       Date:  2018-01-17       Impact factor: 14.919

View more
  1 in total

1.  How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.

Authors:  Ari Voutilainen; Jyrki K Virtanen; Sari Hantunen; Tarja Nurmi; Petra Kokko; Tomi-Pekka Tuomainen
Journal:  Andrologia       Date:  2022-02-28       Impact factor: 2.532

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.